专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010077061A3 PHARMACEUTICAL FORMULATIONS CONTAINING ANTIVIRAL DRUGS 审中-公开
标题翻译：含有抗病毒药物的药物制剂
公开(公告)号：WO2010077061A3
公开(公告)日：2010-11-04
申请号：PCT/KR2009007880
申请日：2009-12-29
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG WUK , JUN SUNG SOO , LEE AH RAM
发明人： KIM SUNG WUK , JUN SUNG SOO , LEE AH RAM
IPC分类号： A61K31/70 , A61K9/22 , A61K31/513 , A61K47/30 , A61K47/38 , A61K47/42 , A61P31/12
CPC分类号： A61K31/513 , A61K31/70 , A61K47/38 , A61K47/42
摘要： The present invention relates to pharmaceutical formulations containing antiviral drugs and sustained-release materials, and to pharmaceutical formulations having an immediate release compartment containing drugs associated with cytochrome P450, as well as an extended release compartment containing antiviral drugs and sustained-release materials. The formulations of the present invention reduce interactions between antiviral drugs to increase the effects of the drugs and to decrease side effects.
摘要翻译：本发明涉及含有抗病毒药物和缓释材料的药物制剂，以及具有含细胞色素P450相关药物的速释隔室的药物制剂，以及含有抗病毒药物和缓释材料的缓释隔室。本发明的制剂减少抗病毒药物之间的相互作用以增加药物的作用并减少副作用。

2. 发明申请

WO2010098627A3 PHARMACEUTICAL PREPARATION 审中-公开
标题翻译：药物制剂
公开(公告)号：WO2010098627A3
公开(公告)日：2011-01-06
申请号：PCT/KR2010001246
申请日：2010-02-26
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , LEE AH RAM , JANG SEOK YOUNG , PARK YUN SANG , LEE NAYOUNG , LEE EUNMI
发明人： KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , LEE AH RAM , JANG SEOK YOUNG , PARK YUN SANG , LEE NAYOUNG , LEE EUNMI
IPC分类号： A61K9/22 , A61K9/20 , A61K47/30 , A61P35/00
CPC分类号： A61K9/209 , A61K31/436 , A61K31/4706 , A61K31/505 , A61K31/7068 , A61K2300/00
摘要： The present invention relates to a pharmaceutical preparation comprising an immediate-release compartment and an extended-release compartment, wherein said immediate-release compartment and said extended-release compartment each contain different oral anticancer drugs as active ingredients. The pharmaceutical preparation of the present invention is advantageous in that drug interactions and side effects of oral anticancer drugs can be minimized, and the administration of the pharmaceutical preparation can be easily performed.
摘要翻译：本发明涉及包含立即释放室和延长释放室的药物制剂，其中所述立即释放室和所述延长释放室各自含有不同的口服抗癌药物作为活性成分。本发明的药物制剂的优点在于能够使口服抗癌药物的药物相互作用和副作用最小化，能容易地进行药物制剂的给药。

3. 发明申请

WO2010077096A3 DRUG DELIVERY SYSTEM 审中-公开
标题翻译：药物输送系统
公开(公告)号：WO2010077096A3
公开(公告)日：2010-11-25
申请号：PCT/KR2009007968
申请日：2009-12-30
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG WUK , JUN SUNG SOO , LEE AH RAM
发明人： KIM SUNG WUK , JUN SUNG SOO , LEE AH RAM
IPC分类号： A61J3/06 , A61J3/00
CPC分类号： A61J3/071 , A61M31/002
摘要： The present invention relates to a drug delivery system comprising: a plastic soft capsule having an enclosed space defined therein; a tablet to be kept in the interior space of the capsule; and a drug filling portion, wherein part of the tablet's surface is adhered closely to the inside surface of the capsule and the drug filling portion is composed of the remaining area of the interior space excluding the space occupied by the tablet. Examples of benefits of a drug delivery system according to the present invention include a system which is capable of controlling drug release, physically separating and then filling the same or different active ingredients contained in the system to prevent chemical reactions induced by physical blending of those ingredients, preventing interaction between drugs that can occur inside the body when different kinds of drugs are co-administered, and storing a large amount of active ingredients.
摘要翻译：药物输送系统技术领域本发明涉及一种药物输送系统，其包括：塑料软胶囊，其中限定有封闭空间; 将片剂保存在胶囊的内部空间中; 和药物填充部分，其中片剂表面的一部分紧密地粘附到胶囊的内表面，并且药物填充部分由除了片剂占据的空间之外的内部空间的剩余区域组成。根据本发明的药物递送系统的益处的实例包括能够控制药物释放，物理分离然后填充系统中包含的相同或不同活性成分以防止由这些成分物理混合诱导的化学反应的系统，当联合施用不同种类的药物时，防止在体内可能发生的药物之间的相互作用，并且储存大量的活性成分。

4. 发明申请

WO2012036410A3 MODIFIED HUMAN TUMOR NECROSIS FACTOR RECEPTOR-1 POLYPEPTIDE OR FRAGMENT THEREOF, AND METHOD FOR PREPARING SAME 审中-公开
公开(公告)号：WO2012036410A3
公开(公告)日：2012-05-31
申请号：PCT/KR2011006621
申请日：2011-09-07
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG WUK , JUN SUNG SOO , PARK SEUNG KOOK , KIM SONG YOUNG , KIM EUN SUN , JEONG JAE KAP , KIM HA NA , SONG YEON JUNG
发明人： KIM SUNG WUK , JUN SUNG SOO , PARK SEUNG KOOK , KIM SONG YOUNG , KIM EUN SUN , JEONG JAE KAP , KIM HA NA , SONG YEON JUNG
IPC分类号： C07K14/705 , A61K38/19 , C07K14/525 , C12N15/63
CPC分类号： C07K14/7151 , A61K38/00 , A61K38/19 , C07K14/525 , C07K14/705 , C12N15/63
摘要： The present invention relates to a modified human tumor necrosis factor receptor-1 polypeptide to bind to a tumor necrosis factor in vivo or ex vivo, or to a fragment thereof. According to the present invention, the modified human tumor necrosis factor receptor-1 polypeptide or the fragment thereof exhibits improved binding force to the tumor necrosis factor.

5. 发明申请

WO2011049400A3 PHARMACEUTICAL COMPOSITION CONTAINING ACID ADDITION SALT OF N,N-DIMETHYL IMIDOCARBONIMIDIC DIAMIDE FOR ANTI-CANCER 审中-公开
标题翻译：含有N，N-二甲基咪唑并二恶烷的抗酸剂的酸加成盐的药物组合物
公开(公告)号：WO2011049400A3
公开(公告)日：2011-11-03
申请号：PCT/KR2010007273
申请日：2010-10-22
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG WUK , JUN SUNG SOO , KIM YOUNG WOONG , OH BYUNG KYU , LEE SEUNG HO
发明人： KIM SUNG WUK , JUN SUNG SOO , KIM YOUNG WOONG , OH BYUNG KYU , LEE SEUNG HO
IPC分类号： A61K31/155 , A61P3/04 , A61P3/06 , A61P3/10
CPC分类号： A61K31/155 , A61K45/06 , A61K2300/00
摘要： Provided is a use for anticancer of dichloroacetic acid salt or aminooxyacetic acid salt of N,N-dimethyl imidodicarbonimidic diamide (metformin). According to the present invention, the acid addition salt of metformin synergistically causes anticancer effect by AMPK enzyme activation of metformin and anticancer effect of organic acids used as a salt, and thus shows a remarkable anticancer effect. In addition, the acid addition salt has superior physiochemical properties such as solubility, stability, non-hygroscopicity, processibility as a tablet formulation and the like, and has lower toxicity compared with metformin hydrochloride. Therefore, the acid addition salt can be useful as a pharmaceutically acceptable salt.
摘要翻译：提供了N，N-二甲基亚氨基二甲酰亚胺二酰胺（二甲双胍）的二氯乙酸盐或氨基氧乙酸盐的抗癌剂的用途。根据本发明，二甲双胍的酸加成盐协同地引起二甲双胍的AMPK酶活化和作为盐的有机酸的抗癌作用的抗癌作用，因此显示出显着的抗癌作用。此外，酸加成盐具有优异的物理化学性质如溶解性，稳定性，非吸湿性，作为片剂制剂的加工性等，并且与二甲双胍盐酸盐相比具有较低的毒性。因此，酸加成盐可用作药学上可接受的盐。

6. 发明申请

WO2011049350A2 MODIFIED HUMAN TUMOR NECROSIS FACTOR RECEPTOR-1 POLYPEPTIDE OR FRAGMENT THEREOF, AND METHOD FOR PREPARING SAME 审中-公开
标题翻译：修饰的人肿瘤坏死因子受体-1聚糖或其片段及其制备方法
公开(公告)号：WO2011049350A2
公开(公告)日：2011-04-28
申请号：PCT/KR2010007160
申请日：2010-10-19
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG WUK , JUN SUNG SOO , PARK SEUNG KOOK , KIM SONG YOUNG , KIM EUN SUN , JEONG JAE KAP , KIM HA NA , SONG YEON JUNG
发明人： KIM SUNG WUK , JUN SUNG SOO , PARK SEUNG KOOK , KIM SONG YOUNG , KIM EUN SUN , JEONG JAE KAP , KIM HA NA , SONG YEON JUNG
IPC分类号： C07K14/705 , C12N15/28 , C12N15/63
CPC分类号： C07K14/70578
摘要： The present invention relates to a modified human tumor necrosis factor receptor-1 polypeptide to be coupled to a tumor necrosis factor in vivo or ex vivo, or to a fragment thereof. The modified human tumor necrosis factor receptor-1 polypeptide or the fragment thereof according to the present invention exhibit improved resistance against in vivo protease activity, and thus exhibit improved bioavailability and an improved absorption rate.
摘要翻译：本发明涉及在体内或体外与肿瘤坏死因子偶联的修饰的人肿瘤坏死因子受体-1多肽或其片段。根据本发明的修饰的人肿瘤坏死因子受体-1多肽或其片段表现出改善的抗体内蛋白酶活性，因此表现出改进的生物利用度和改善的吸收速率。

7. 发明申请

WO2011008053A3 PROPIONATE OF N,N-DIMETHYL IMIDOCARBON IMIDIC DIAMIDE, METHOD OF PREPARING SAME, AND PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS CONTAINING SAME 审中-公开
标题翻译： N，N-二甲基间苯二甲酰胺二酰胺的丙酸盐，其制备方法，以及含有该组分的药物组合物和组合物
公开(公告)号：WO2011008053A3
公开(公告)日：2011-04-21
申请号：PCT/KR2010004673
申请日：2010-07-16
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG WUK , JUN SUNG SOO , MIN CHANGHEE , KANG MIN SEOK , KIM YONG EUN , KOO JA SEONG
发明人： KIM SUNG WUK , JUN SUNG SOO , MIN CHANGHEE , KANG MIN SEOK , KIM YONG EUN , KOO JA SEONG
IPC分类号： C07C279/26 , C07C53/122 , C07C277/00
CPC分类号： C07C53/122 , C07C277/00 , C07C279/26
摘要： The present invention provides metformin propionate, a method of preparing the same, and pharmaceutical compositions and combinations containing the same. The metformin propionate according to the present invention has an excellent pharmacological effect as compared with metformin hydrochloride and is capable of achieving a therapeutic purpose by administering an amount less than metformin hydrochloride. Furthermore, the metformin propionate has excellent physicochemical properties, such as solubility, stability, hygroscopicity and adsorption preventing property, in processibility of formulations and thereby is capable of being usefully utilized as a pharmaceutically acceptable salt of the metformin.
摘要翻译：本发明提供了丙酸二甲双胍，其制备方法，以及含有其的药物组合物和组合。根据本发明的二甲双胍丙酸盐与二甲双胍盐酸盐相比具有优异的药理学效果，并且通过施用少于二甲双胍盐酸盐的量能够达到治疗目的。此外，丙酸二甲双胍具有优异的物理化学性质，例如溶解性，稳定性，吸湿性和吸附防止性，制剂的可加工性，因此能够有效地用作二甲双胍的药学上可接受的盐。

8. 发明申请

WO2010044582A3 N1-2-THIOPHENE-2-YLETHYL-N2-SUBSTITUTED BIGUANIDE DERIVATE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENTS 审中-公开
标题翻译： N1-2-噻吩-2-甲基-2-氮取代的双胍衍生物，其制备方法和含有其作为活性成分的药物组合物
公开(公告)号：WO2010044582A3
公开(公告)日：2010-08-19
申请号：PCT/KR2009005856
申请日：2009-10-13
申请人： HANALL BIOPHARMA CO LTD , KOREA RES INST CHEM TECH , KIM SUNG WUK , JUN SUNG SOO , CHEON HYAE GYEONG , KIM KWANG ROK , RHEE SANG DAL , JUNG WON HOON , LEE JONG CHEOL
发明人： KIM SUNG WUK , JUN SUNG SOO , CHEON HYAE GYEONG , KIM KWANG ROK , RHEE SANG DAL , JUNG WON HOON , LEE JONG CHEOL
IPC分类号： C07D333/08
CPC分类号： C07D333/20
摘要： The present invention relates to an N1-2-thiophene-2-ylethyl-N2-substituted biguanide derivate expressed in Chemical Formula 1, a pharmaceutically allowable salt thereof, a preparation method thereof, and a pharmaceutical composition containing the same as active ingredients. The N1-2-thiophene-2-ylethyl-N2-substituted biguanide derivate of the present invention shows a superior hypoglycemic action and a superior hypolipidemic action even at a low dosage as compared with conventional drugs, and thus can be used for prevention and treatment of diabetes, non-insulin-dependent diabetes, obesity, the metabolic syndrome and arteriosclerosis, or cancer involving P53 gene deficiency.
摘要翻译：本发明涉及化学式1表示的N1-2-噻吩-2-乙基-N2-取代双胍衍生物，其药学上允许的盐，其制备方法和含有该活性成分的药物组合物。与常规药物相比，本发明的N1-2-噻吩-2-乙基-N2-取代双胍衍生物即使在低剂量下也显示出优异的降血糖作用和优异的降血脂作用，因此可用于预防和治疗糖尿病，非胰岛素依赖性糖尿病，肥胖症，代谢综合征和动脉硬化，或涉及P53基因缺陷的癌症。

9. 发明申请

WO2012087017A3 MODIFIED HUMAN TUMOR NECROSIS FACTOR RECEPTOR-1 POLYPEPTIDE OR FRAGMENT THEREOF AND METHOD FOR PREPARING SAME 审中-公开
标题翻译：修饰的人肿瘤坏死因子受体-1多肽或其片段及其制备方法
公开(公告)号：WO2012087017A3
公开(公告)日：2012-08-16
申请号：PCT/KR2011009914
申请日：2011-12-21
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG WUK , JUN SUNG SOO , PARK SEUNG KOOK , KIM SONG YOUNG , KIM EUN SUN , JEONG JAE KAP , KIM HA NA , SONG YEON JUNG
发明人： KIM SUNG WUK , JUN SUNG SOO , PARK SEUNG KOOK , KIM SONG YOUNG , KIM EUN SUN , JEONG JAE KAP , KIM HA NA , SONG YEON JUNG
IPC分类号： C07K14/715 , A61K38/17 , A61P35/00 , C12N15/12
CPC分类号： C07K14/7151 , A61K38/00 , C07K14/70575
摘要： The present invention relates to a modified human tumor necrosis factor receptor-1 polypeptide or a fragment thereof which is bound to a tumor necrosis factor in vivo or ex vivo. The modified human tumor necrosis factor receptor-1 polypeptide or the fragment thereof according to the present invention exhibits improved binding force to the tumor necrosis factor and improved protease resistance.
摘要翻译：本发明涉及在体内或离体结合肿瘤坏死因子的修饰的人肿瘤坏死因子受体-1多肽或其片段。根据本发明的修饰的人肿瘤坏死因子受体-1多肽或其片段表现出对肿瘤坏死因子的改进的结合力和改善的蛋白酶抗性。

10. 发明申请

WO2011049350A3 MODIFIED HUMAN TUMOR NECROSIS FACTOR RECEPTOR-1 POLYPEPTIDE OR FRAGMENT THEREOF, AND METHOD FOR PREPARING SAME 审中-公开
标题翻译：修饰的人肿瘤坏死因子受体-1多肽或其片段及其制备方法
公开(公告)号：WO2011049350A3
公开(公告)日：2011-10-13
申请号：PCT/KR2010007160
申请日：2010-10-19
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG WUK , JUN SUNG SOO , PARK SEUNG KOOK , KIM SONG YOUNG , KIM EUN SUN , JEONG JAE KAP , KIM HA NA , SONG YEON JUNG
发明人： KIM SUNG WUK , JUN SUNG SOO , PARK SEUNG KOOK , KIM SONG YOUNG , KIM EUN SUN , JEONG JAE KAP , KIM HA NA , SONG YEON JUNG
IPC分类号： C07K14/705 , C12N15/28 , C12N15/63
CPC分类号： C07K14/70578
摘要： The present invention relates to a modified human tumor necrosis factor receptor-1 polypeptide to be coupled to a tumor necrosis factor in vivo or ex vivo, or to a fragment thereof. The modified human tumor necrosis factor receptor-1 polypeptide or the fragment thereof according to the present invention exhibit improved resistance against in vivo protease activity, and thus exhibit improved bioavailability and an improved absorption rate.
摘要翻译：本发明涉及体内或离体与肿瘤坏死因子偶联的修饰的人肿瘤坏死因子受体-1多肽或其片段。根据本发明的修饰的人肿瘤坏死因子受体-1多肽或其片段表现出对体内蛋白酶活性的改善的抗性，并因此表现出改善的生物利用度和改善的吸收率。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式